Full-length Multipass Transmembrane Proteins

Solutions for Full-length Multipass Transmembrane Protein Banner

OriGene's Solutions for Transmembrane Protein Research

We offer full-length multipass transmembrane protein in four platforms: Synthetic Nanodisc, Membrane Nanoparticles, Virus-like Particles, and Exosomes. Full-length proteins produced using these platforms leverage the mammalian expression system and maintain their native conformation and activity.

Overcoming Challenges in Transmembrane Protein Studies

Transmembrane proteins (TMPs) are essential for cellular functions and are targets for many drugs. However, TMP research is often hampered by challenges such as:

  • Loss of functionality outside the membrane
  • Low expression levels
  • Aggregation tendencies due to hydrophobic nature

These challenges make it difficult to study and utilize TMPs in drug discovery.

View all Transmembrane Protein Products

Platform #1: Synthetic Nanodiscs

OriGene's Synthetic Nanodiscs are directly prepared from cells, using polymers as detergents to dissolve cell membranes and form Nanodiscs around membrane proteins. This process enables high-homogeneity purification of membrane proteins under aqueous conditions.

View all Synthetic Nanodiscs Products

Nanodisc Workflow
Figure 1: Synthetic Nanodisc for the preparation of the full-length multipass transmembrane proteins

Key Benefits

  • Highly purified membrane protein
  • Highly soluble in aqueous solutions
  • Highly stable, available in lyophilized form
  • Biologically active
  • No detergent to interfere with cell-based assays
  • No membrane scaffold backbone proteins

Applications

  • ELISA
  • SPR affinity analysis
  • Phase display screening
  • Cell-based assays
  • CAR-T cell screening
  • Protein crystal structure analysis

Validation Data:

Human CLDN18.2 full-length protein - Synthetic Nanodisc (TP721388)

Validation Data Image 1
Validation Data Image 2
Validation Data Image 3
Human CLDN18.2-Nanodisc on SDS-PAGE
Human CLDN18.2-Nanodisc (0.2μg/per well) binds to anti- CLDN18.2 mAb (EC50 593.6ng/ml).
Human CLDN18.2-Nanodisc can bind the Anti-CLDN18.2 antibody with an affinity constant of 1.619 nM, as determined in an SPR assay.

Platform #2: Membrane Nanoparticles (MNPs)

OriGene's high-purity MNPs are produced by extracting and extruding membranes from HEK293 cells, overexpressing target proteins. These nanoparticles leverage cell membranes' natural functions, ensuring high biocompatibility, specificity, and minimal side effects.

View all MNPs Products

Nanodisc Workflow
Figure 2: MNPs for the preparation of the full-length multipass transmembrane proteins

Key Benefits

  • High display density of target membrane proteins
  • Native structure and orientation of transmembrane protein
  • Soluble in aqueous solution
  • Detergent-free purification process
  • Strong immunogenicity
  • Purify membrane proteins that can't be produced via VLPs and EXOs

Applications

  • ELISA
  • SPR affinity analysis
  • Phase display screening
  • Cell-based assays
  • CAR-T cell screening

Validation Data:

Human CCR8 Recombinant Protein, Membrane Nanoparticle (TP721378)

Validation Data

Flow cytometry validation of Human CCR8 MNP protein: CCR8 full-length MNP stained (A) only with Goat anti-human IgG 488 secondary antibody; (B) with an irrelevant antibody at 2 μg/mL, followed by Goat anti-human IgG 488 secondary antibody; (C) with anti-CCR8 antibody at 2 μg/mL, followed by Goat anti-human IgG 488 secondary antibody; and (D) Control MNP stained with anti-CCR8 antibody at 2 ug/mL, followed by Goat anti-human IgG 488 secondary antibody.

Platform #3: Virus-like Particles (VLPs)

Virus-like particles are self-assembling nanoparticles that mimic viruses structurally but lack a viral genome. Purified VLPs have target membrane proteins embedded in a bilayer phospholipid membrane, closely resembling their natural state.

View all VLPs Products

Nanodisc Workflow
Figure 3. VLP for the preparation of the full-length multipass transmembrane proteins

Key Benefits

  • High display density of target membrane proteins
  • Mimic native structure and orientation of transmembrane protein
  • Detergent-free purification process
  • Strong immunogenicity from virus proteins

Applications

  • ELISA
  • SPR affinity analysis
  • Phase display screening
  • Immunization
  • Cell-based assays
  • CAR-T cell screening

Validation Data:

Human CLDN18.2 Recombinant Protein, Virus-like Particle (TP721381)

Validation Data

ELISA evaluation of Human CLDN18.2 VLP protein: ELISA plates were pre-coated with 0.5 ug/per well-purified human Claudin 18.2 VLP. Serially diluted Anti-Claudin18.2 monoclonal antibody (Zolbetuximab biosimilar) solutions were added, washed, and incubated with the secondary antibody before ELISA reading. From the above data, the EC50 for Zolbetuximab biosimilar binding with Claudin18.2 is 15.37ng/ml.

Validation Data

Flow cytometry validation Human CLDN18.2 VLP protein: ELISA plates were pre-coated with 0.5 ug/per well-purified human Claudin 18.2 VLP. Serially diluted Anti-Claudin18.2 monoclonal antibody (Zolbetuximab biosimilar) solutions were added, washed, and incubated with the secondary antibody before ELISA reading. From the above data, the EC50 for Zolbetuximab biosimilar binding with Claudin18.2 is 15.37ng/ml.

Platform #4: Exosomes (EXOs)

Exosomes are membrane-bound nanoparticles secreted through multivesicular body fusion with the cell membrane. Like VLPs, EXOs exhibit excellent immunogenicity due to their plasma membrane-like structure. Overexpressed membrane proteins can integrate into exosome membranes, allowing for purification and downstream studies. Unlike VLPs, purified EXOs have minimal cytotoxicity. However, membrane protein incorporation and secretion into exosomes can be selective.

View all EXOs Products

Nanodisc Workflow
Figure 4. VLP for the preparation of the full-length multipass transmembrane proteins

Key Benefits

  • High display density of target membrane proteins
  • Mimic native structure and orientation of transmembrane protein
  • Detergent-free purification process
  • Strong immunogenicity from virus proteins

Applications

  • ELISA
  • SPR affinity analysis
  • Phase display screening
  • Immunization
  • Cell-based assays
  • CAR-T cell screening

Validation Data:

Human CD24 Recombinant Protein, Exosome (TP721379)

Validation Data Image 1
Validation Data Image 2
ELISA evaluation of Human CD24 EXO protein: ELISA plates were pre-coated with purified human CD24 exosome (0.5 μg/per well). Serially diluted Anti-CD24 monoclonal antibody solutions were added, washed, and incubated with the secondary antibody before the ELISA reading. From the above data, the EC50 is 69.61 ng/ml.
Nanoparticle Tracking Analysis of CD24 Exosomes